1 September 2006 in Journal of Pineal Research
1 January 2016 in Journal of Complementary Medicine Research
To determine the effect of cinnamon on fasting blood glucose, hemoglobin (Hb) A1c, and oxidative stress markers in poorly controlled type 2 diabetes. A total of 25 type 2 diabetic patients of both sexes, aged 49.1 ± 6.0, treated only with hypoglycemic agent sulfonylurea (glibenclamide) were randomly assigned to receive either 1 g of cinnamon or placebo daily for 12 weeks. A highly significant (P ≤ 0.001) reduction (10.12%) of fasting blood glucose level after 6 and 12 weeks of treatment 10.12% and 17.4%, respectively, compared to baseline value and to placebo group at corresponding duration. Meanwhile, the value of glycosylated Hb reduced in cinnamon treated group by (2.625%) and (8.25%) after 6 and 12 weeks, respectively, although this reduction was non-significant compared to baseline value. Concerning the oxidative stress markers, the level of serum glutathione showed highly significant (P ≤ 0.001) elevation after 12 weeks as compared to baseline value and placebo group at corresponding duration, malondialdehyde serum level decreased after treatment of diabetic patients with cinnamon resulted in highly significant (P ≤ 0.001) reduction after 6 and 12 weeks compared to placebo group, but when compared to baseline value, there is a (15%) reduction only after 12 weeks of treatment which was considered highly significant (P ≤ 0.001) change, Finally, administration of cinnamon to diabetic patients for 12 weeks resulted in significant (P ≤ 0.05) elevation of superoxide dismutase level. Intake of 1 g of cinnamon for 12 weeks reduces fasting blood glucose and glycosylated Hb among poorly controlled type 2 diabetes patients, as well as, there is improvement in the oxidative stress markers, indicating the beneficial effect of adjuvant cinnamon as anti-diabetic and antioxidant along with conventional medications to treat poorly controlled type 2 diabetes mellitus.
1 October 2006 in Saudi Medical Journal
OBJECTIVE: This project was designed to evaluate the effects of melatonin and zinc on the glycemic control in type 2 diabetes mellitus (T2DM) patients with inadequate response to the oral hypoglycemic agent metformin. METHODS: A placebo controlled, double-blind clinical trial was performed at the Specialized Center for Endocrinology and Diabetes, Al-Rusafa Directorate of Health, Baghdad, Iraq during the period from February to July 2005, in which 46 type 2 diabetic patients were selected and allocated into 3 groups, these groups were treated with single daily oral doses of both 10 mg melatonin and 50 mg zinc acetate alone; 10 mg melatonin and 50 mg zinc acetate in addition to the regularly used metformin or placebo, given at bed time for 90 days. We measured the fasting plasma glucose (FPG), glycated hemoglobin (HbA1C) and serum C-peptide before starting the treatment (zero time) and after 30 and 90 days of treatment. We also performed post-prandial glucose excursion test (PPGE) for selected patients from the second and third groups before starting the treatment and after 90 days. RESULTS: Daily administration of melatonin and zinc improved the impaired fasting and post-prandial glycemic control and decreased the level of glycated hemoglobin; addition of this treatment regimen in combination with metformin improved the tissue responses to this oral hypoglycemic agent. CONCLUSION: The combination of melatonin and zinc acetate, when used alone or in combination with metformin improves fasting and post-prandial glycemic control in T2DM patients.
1 January 2012 in Spatula DD
1 January 2014 in Journal of Complementary Medicine Research
Giardia lamblia is the most common intestinal parasite of humans identified worldwide. In spite of metronidazole (Met) is the most commonly used drug for the treatment of giardiasis in humans, low patient compliance and side-effects, especially in children encourage efforts to look for new and safe agent; many plants used in folk medicine thought to have antigiardial effect, Anethum graveolens (AG) (dill) is an annual herb cultivated in Iraq used both as a medicinal agent and as food spice. The aim of this study was to investigate the effect of aqueous extract (AE) of AG leave in the treatment of giardiasis, compared with that of standard drug Met. A prospective randomized clinical trial was carried out on 28 pediatric patients of both sexes with age of <1 year ranging from 3 to 11 months, who attend to outpatient private clinic in Baghdad for a period of 6 months from June 2013 to December 2013,Patients participate in this study were allocated into two groups Group A composed of 14 patients treated with Met 15 mg/kg 3 times a day for 5 days. Group B composed of 14 patients treated with AGAE 1 ml 3 times a day for 5 days. Stool samples were collected at 0 time before administration of treatment, after 5 days and after 14 days from starting the treatments to check the efficacy of treatment. Administration of AGAE results in a significant decrease in incidence of G. lamblia after 5 days of treatment indicating the efficacy of AGAE in the treatment of giardiasis a result that is comparable to that of Met. This study showed that pediatric patients with giardiasis may benefit from 5 days treatment with AGAE administered as 1 ml 3 times daily, the improvement in the symptom with this herbal agent was comparable to the standard pharmacological agent Met; results showed that AG is safe and tolerable over treatment course.